The use of cytokine inhibitors. A new therapeutic insight into heart failure

International Journal of Cardiology

Volumn 62, Issue SUPPL. 1, 1997, Pages S3-

  Matsumori, Akira ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cytokine inhibitors; Heart failure; New therapy; Role of NO

Indexed keywords

AMRINONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; DRUG EFFECT; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; INFLAMMATION; INOTROPISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

EID: 0031467021     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0167-5273(97)00206-4     Document Type: Conference Paper

References (79)

1. Oppenheim JJ, Saklatvala J. Cytokines and their receptors, in: Oppenheim JJ, Rossio JL, Gearing AJH, editors. Clinical Applications of Cytokine. Role in pathogenesis, Diagnosis, and Therapy. Oxford: Oxford University Press, 1993:3-15.
2. Matsumori A. Molecular and immune mechanism in the pathogenesis of cardiomyopathy. Role of viruses, cytokines, and nitric oxide. Jpn Circ J. 61:1997;275-291.
3. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
4. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
5. Katz S.D., Rao R., Berman J.W.et al. Pathophysiological correlates of increased serum tumour necrosis factor in patients with congestive heart failure; Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 90:1994;12-16.
6. Torre-Amione G., Kapadia S., Lee J., Bies R.D., Lebovitz R., Mann D.L. Expression and functional significance of tumour necrosis factor receptors in human myocardium. Circulation. 92:1995;1487-1493.
7. Latini R., Bianchi M., Correale E.et al. Cytokine in acute myocardial infarction: Selective increase in circulating tumour necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol. 23:1994;1-6.
8. Kapadia S., Torre-Amione G., Yokoyama T., Mann D.L. Soluble TNF binding proteins modulate the negative inotropic properties TNF-α in vitro. Am J Physiol. 268:1995;H517-H525.
9. Ferrari R., Bachetti T., Confortini R.et al. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
10. Packer M. Is tumour necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 92:1995;1379-1382.
11. Limas C.J., Goldenberg I.F., Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation. 91:1995;631-634.
12. Miyao Y., Yasue H., Ogawa H.et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 126:1993;1299-1304.
13. Neumann F.-J., Ott I., Gawaz M.et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 92:1995;748-755.
14. Kanda T., Hirao Y., Oshima S.et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol. 77:1996;304-307.
15. Kukielka G.L., Smith C.W., LaRosa G.J.et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest. 95:1995;89-103.
16. Matsumori A., Furukawa Y., Hashimoto T.et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemotactic protein-I are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 29:1997;419-423.
17. Ghezzi P., Dinarello C.A., Bianchi M., Rosandich M.E., Repine J.E., White C.W. Hypoxia increases production of interleukin-1 and tumour necrosis factor by human mononuclear cells. Cytokine. 3:1991;189-194.
18. Yamauchi-Takihara K., Ihara Y., Ogata A., Yoshizaki K., Azuma J., Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 91:1995;1520-1524.
19. Kapadia S., Lee J., Torre-Amione G., Birdsall H.H., Ma T.S., Mann D.L. Tumour necrosis factor-a gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 96:1995;1042-1052.
20. Tsujino M., Hirata Y., Imai T.et al. Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiocytes. Circulation. 90:1994;375-383.
21. Balligand J.-L., Ungureanu D., Kelly R.A., Pimental D., Michel T., Smith T.W. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 91:1993;2314-2319.
22. Evans H.G., Lewis M.J., Shar A.M. Interleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res. 27:1993;1486-1490.
23. i and cell contraction in cultured chick ventricular myocytes. Circ Res. 75:1994;285-295.
24. Hosenpud J.D., Campbell S.M., Mendelson D.J. Interleukin-1 induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 8:1989;460-468.
25. Weisensee D., Bereiter-Hahn J., Schoeppe W., Friedrich L.W. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol. 15:1993;581-587.
26. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
27. Li Y.-H., Rozanski G.J. Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res. 27:1993;525-530.
28. 2+ current by interleukin-1β in cultured rat ventricular myocytes. Am J Physiol. 268:1995;C339-C349.
29. Libby P., Warner S.J., Friedman G.B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoid. J Clin Invest. 81:1988;487-498.
30. Boluyt M.O., O'Neill L., Meredith A.L.et al. Alternation in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding. extracellular matrix components. Circ Res. 75:1994;23-32.
31. Pinsky D.J., Cai B., Yang X., Rodriguez C., Sciacca R.R., Cannon P.J. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β J Clin Invest. 95:1995;677-685.
32. Woodley S.L., McMillan M., Shelby J.et al. Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation. 83:1991;1410-1418.
33. Seko Y., Ishiyama S., Nishikawa T.et al. Restricted usage of T cell receptor Vα-Vβ genes in infiltrating cells in the hearts of patients with acute myocarditis and dilated cardiomyopathy. J Clin Invest. 96:1995;1035-1041.
34. Thaik C.M., Calderone A., Takahashi N., Colucci W.S. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 96:1995;1093-1099.
35. Beck A.C., Ward J.H., Hammond E.H., Wray R.B., Samlowski W.E. Cardiomyopathy associated with high-dose interleukin-2 (IL-2) therapy. West J Med. 158:1991;293-296.
36. Sobotka P.A., McMannis J., Fisher R.I., Stein D.G., Thomas J.X. Jr. Effects of interleukin 2 on cardiac function in the isolated rat heart. J Clin Invest. 86:1990;845-850.
37. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumour necrosis factor-α in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
38. Ungureanu-Longrois D., Balligand J.-L., Simmons W.W., Okada I., Kobzik L., Lowenstein C.J.et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res. 77:1995;494-502.
39. Schulz R., Panas D.L., Catena R., Moncada S., Olley P.M., Lopaschuck G.D. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α Br J Pharmacol. 114:1995;27-34.
40. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA. 92:1995;4862-4866.
41. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 105:1994;897-904.
42. Matsumori A. Animal models: Pathological findings and therapeutic considerations, in: Banatvala JE, editor. Viral infection of the heart, London: Edward Arnold, 1993:110-137.
43. Shioi T., Matsumori A., Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 94:1996;2930-2937.
44. Jaattela M. Biology of disease: Biologic activities and mechanisms of action of tumour necrosis factor-alpha/cachectin. Lab Invest. 64:1991;724-742.
45. Taniguchi T. Regulation of cytokine gene expression. Ann Rev Immunol. 6:1988;439-464.
46. Efrat S., Pilo S., Kaempfer R. Kinetics of induction and molecular size of mRNAs encoding human interleukin-2 and gamma-interferon. Nature. 297:1982;236-239.
47. Kodama M., Hanawa H., Saeki M.et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 75:1994;278-284.
48. Sasasayama S. What do the newer inotropic drugs have to offer? Cardiovasc. Drugs Therapy. 6:1992;15-18.
49. Feldman A.M., Bristow M.R., Parmley W.W.et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
50. Matsui S., Matsumori A., Matoba Y., Uchida A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumour necrosis factor-α production. J Clin Invest. 94:1994;1212-1217.
51. Shioi T., Matsumori A., Matsui S., Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci. 54:1994;PL11-16.
52. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955-958.
53. Sato Y., Matsumori A., Sasayama S. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol. 27:1995;2265-2273.
54. Matsui S., Matsumori A., Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci. 55:1994;1735-1741.
55. Matsumori A., Ono K., Sato Y., Shioi T., Nose Y., Sasayama S. Differential modulation of cytokine production by drugs: Implication for therapy in heart failure. J Mol Cell Cardiol. 28:1996;2491-2499.
56. Hurme M. Modulation of interleukin-1β production by cyclic AMP in human monocytes. FEBS Lett. 263:1990;35-37.
57. Serkkola E., Hurme M., Palkama T. Prolonged elevation of intracellular cyclic AMP activated interleukin-1 production of human peripheral blood monocytes. Scand J Immunol. 35:1992;203-208.
58. Katz A.M. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med. 121:1994;363-371.
59. Gallin E.K. Ion channels in leukocytes. Pharmacol Rev. 71:1991;775-811.
60. Lewis R.S., Cahalan M.D. Ion channels and signal transduction in lymphocytes. Annu Rev Physiol. 52:1990;415-430.
61. + channels depolarize human T lymphocytes: mechanism of antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA. 89:1992;10094-10098.
62. + currents in cytotoxic T lymphocytes. Circ Res. 78:1996;253-261.
63. Iijima T., Taira N. Membrane current changes responsible for the positive inotropic effect of OPC 82I2, a new positive inotropic agent, in single cells of the guinea pig heart. J Pharmacol Exp Ther. 240:1987;657-662.
64. Winlaw D.S., Smythe G.A., Keogh A.M., Schyvens C.C., Spratt P.M., MacDonald P.S. Nitric oxide production and heart failure. Lancet. 344:1994;373-374.
65. De Belder A.J., Radornski M.W., Why H.J.F.et al. Nitric oxide synthase activities in human myocardium. Lancet. 341:1993;84-85.
66. Hattori Y., So S., Hattori S., Kasai K., Shimada S. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res. 30:1995;187-192.
67. Matsumori A., Okada I., Shioi T. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci. 59:1996;PL121-PL125.
68. Kubo S.H., Gollub S., Bourge R. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation. 85:1992;942-949.
69. Koh W.S., Yang K.-H., Kaminski N.E. Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun. 206:1995;703-709.
70. Packer M., Nicod P., Khandheria B.R. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol. 17(suppl):1991;274A.
71. Packer M., O'Connor C.M., Ghali J.K. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 335:1996;1107-1114.
72. Wang W., Matsumori A., Yamada T. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis: A possible mechanism through inhibition of nitric oxide production. Circulation. 95:1997;245-251.
73. Dong R., Liu P., Wee L., Vutany J., Sole M.J. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest. 90:1993;2022-2030.
74. Szabó C., Mitchell J.A., Gross S.S., Thiemermann C., Vane J.R. Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysacchanide. J Pharmacol Exp Ther. 265:1993;674-680.
75. Szabó C., Thiemermann C., Vane J.R. Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun. 196:1993;825-830.
76. Mahe Y., Wakasugi H., Scamps C., Chouaib S., Tursz T. Role of calcium on interleukin-1 production by monocytes: its relevance during T cell proliferation. Lymphokine Cytokine Res. 10:1991;165-172.
77. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
78. Beckman J.S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol. 15:1991;53-59.
79. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 87:1990;1620-1624.